

SUBJECT INDEX

A

- Acetyl-low-density-lipoprotein receptor, 220-21
- Acute renal failure
 - ischemic, 523-42
- Adolescents
 - suicide among, 38-40
 - child abuse and, 38
 - clustering of, 39
 - substance abuse and, 38
- Adult respiratory distress syndrome, 26, 341, 344-45, 347, 352, 430-31
 - liver transplantation and, 430-31
 - open lung biopsy and, 26
- Affective disorders
 - suicide and, 40-41
- African Americans
 - suicide and homicide among, 38
- AIDS
 - Epstein-Barr virus infections and, 438, 443
 - schistosomiasis vaccine and, 217
- AIK-C vaccine for measles, 461
- Alcohol dependence
 - suicide and, 40
- Allergic bronchopulmonary helminthiasis, 418
- Allergic bronchopulmonary aspergillosis, 422
- Allergic disease
 - eosinophils and, 209-17
 - Fcε-RII-bearing mononuclear phagocytes and, 209-17
 - IgE antibody and, 209-17
 - platelets and, 209-17
- Allografts
 - human pancreas, 395-413
 - renal
 - ischemic injury to, 523-42
 - See also Transplantation
- Alveolar hemorrhage, 425-429
- Alveolitis, 17-32, 417
 - antifibrotic agents and, 17
 - bronchoalveolar lavage and, 17-18, 20-21
 - chest radiographs and, 17, 19
 - corticosteroids and, 17
 - gallium scanning and, 17, 21
 - high-resolution thin-section computed tomographic scanning and, 17, 20, 22-23, 29

- immunosuppressive/cytotoxic agents and, 17
- Amaurosi's fugax, 302-3
- American Indians
 - suicide among, 38
- 3-Amino-1-hydroxypropylidene-1-l-biphosphonate
 - osteogenesis imperfecta treatment and, 278
- 5-Aminosalicylate (5-ASA)
 - treatment of inflammatory bowel diseases with, 126-31
- Androgen
 - resistance to, 364
- Anemia
 - aplastic
 - Epstein-Barr virus infection and, 441-43
 - chronic hemolytic
 - red cell enzyme deficiencies and, 53-56
- Antibiotic resistance
 - fluoroquinolones and, 467-69
- Antibiotics
 - fluoroquinolones, 465-82
- Anticoagulants, 9-14
 - argatroban, 14
 - dermaton sulfate, 13
 - heparin, 9-13, 175-77
 - low-molecular-weight, 11-13
 - heparinoids, 11-13
 - hirudin, 11, 13-14, 178-79
 - ORG 10172, 13
 - PPACK, 14
- Antihemophilic factor, 325-35
- Antioxidants, 219-24
 - inhibition of atherosclerosis with, 219-24
 - butylated hydroxytoluene, 221, 224
 - carotenoids, 221, 224
 - ubiquinol-10, 221, 224
 - vitamin E, 221, 224
- Antiarrhythmic drug therapy, 116
- Antithrombin III, 10-12
- Antithrombin III-independent inhibitors, 11, 13-14
- Antithrombins, 171-79
 - arginine-glycine-aspartic acid tripeptide-based anti-GPIIb/IIIa agents, 175
 - aspirin, 171, 175-76
 - dipyridamole, 175-77
 - heparin, 9-13, 175-77

- hirudin, 13-14, 175, 178-79
- monoclonal antibody to GPIIb/IIIa, 175, 178-79
- thromboxane A₂ synthetase inhibitor and blocker, 175, 179
- ticlopidine, 171, 175-78
- Argatroban, 14
- Arthritis
 - infectious
 - Lyme disease and, 93, 98-99
 - rheumatoid, 23-26
- Aspergillus* pneumonia
 - susceptibility to transplantation patients and, 426-28
- Aspirin, 171, 175-76
- Assisted/controlled ventilation, 353-55
- Assisted mandatory ventilation, 343-44
- Atherosclerosis, 219-24, 301-13
 - cervical, 302
 - inhibition of
 - antioxidants and, 219-24
 - obstructive extracranial, 307
 - pathogenesis of low-density lipoproteins and, 219-24
- Atherothrombotic disease, 301-13
 - extracranial carotid disease, 301-13
- Atrial natriuretic peptide, 540-41
- Auscultation
 - of neck arteries, 303-4
- 5-Azacytidine, 508-9

B

- Balloon tube tamponade
 - bleeding from esophageal varices and, 69, 72, 79
- Barotrama, 352-53, 359
- Basic fibroblast growth factor, 262
- Bell's palsy, 441
- Beta-globin locus control region, 502-4
- Beta-thalassemia
 - fetal hemoglobin and, 498-500

- Biopsy**
transbronchial lung, 21-22, 26
chronic interstitial lung disease and, 21-22, 26
- Blue sclerae**, 270-71
- Bone disease**
brittle, 269-81
- Bone marrow transplantation**, 428-30, 438
pulmonary complications of, 428-30
- BOOP**, 18, 23, 26
- Borrelia burgdorferi***, 92-102
Lyme disease from, 92-102
See also Lyme disease
- Borrelia* infections**, 92-102
- Borrelia* lymphocytoma**, 96
- Borreliosis**
cardiac, 99-100
neuro-, 96-98
- Breast cancer**
high-risk groups for, 182-83
Wolfe classification of, 182-83
prevention of, 181-92
diet and, 186-87
ovarian suppression and, 187-88
retinoids and, 187
tamoxifen and, 188-92
- Brittle bone disease**, 269-81
- Bronchiectasis**
lung transplantation and, 1, 3
- Bronchiolitis obliterans**, 425, 429-30, 432
- Bronchitis**
Chlamydia pneumoniae and, 317-23
- Bronchoalveolar lavage**, 17-18, 20-21, 28-32, 425, 427-28, 431-32
- Bronchogenic carcinoma**, 195-206
- Bronchoscopy**, 203-4
- Brugia malayi***, 417-19, 421
- Bruit**
asymptomatic
extracranial carotid stenosis and, 304-13
- Budd-Chiari syndrome**, 70
- Butyrates**, 514-15
- C**
- Calcification**
mitral annulus, 303
- Calcitriol**
prevention of secondary hyperparathyroidism and, 227-35
renal disease and, 227-35
See also 1,25-Dihydroxyvitamin D₃
- Cancer**
breast
diet and, 186-87
endometrial
estrogen replacement and, 239, 245-48
estrogen replacement and ovarian, 244-45, 248
familial, 183-84
high risk groups for, 182-83
ovarian suppression and, 187-88
prevention of, 181-92
retinoids and, 188-92
tamoxifen and, 188-92
colon, 61-68
diet and, 61-62
dominant oncogenes and, 61-63
ras gene and, 63-66
gastric, 135-38
Helicobacter pylori infection and, 135-43
lung, 195-206
- Candida***
susceptibility to transplantation patients and, 426-27
- Carcinogenesis**
colon, 61-68
tumor suppressor genes and, 63-68
- Carcinoma**
bronchogenic, 195
medullary thyroid, 253, 263-65
parathyroid, 255-56
- Cardiac borreliosis**, 99-100
- Cardiovascular disease**, 239-48, 301-13
atherosclerosis, 301-13
carotid disease, 301-13
estrogen replacement and, 239, 240-42, 248
transient ischemic attack, 301-13
- Carotid disease**, 301-13
extracranial carotid stenosis, 301
noninvasive assessment of, 301-5, 312-13
risk factor management for, 307-12
- Carotid sinus stimulation**
syncope evaluation and, 296
- c-erb-A***, 363-64
- hormone resistance and**, 364
- Cerebrovascular disease**, 301-12
- Chlamydia pneumoniae***, 317-23
strain TWAR of, 317-23
- Chlamydia trachomatis***, 318
- Chlamydiae***, 317-23
characteristics and properties of, 319
- Chorionic villus analysis**
osteogenesis imperfecta and, 271
- Chromosomal allelic deletion**
colon carcinogenesis and, 63-68
tumor suppression genes and, 63-68
- Chronic granulomatous disease**, 117-22
cytochrome *b* and, 117, 119-22
interferon-gamma and, 117, 121-22
NADPH-oxidase and, 117-22
- Chronic interstitial lung disease**, 18-32
bronchoalveolar lavage and, 17-18, 20-21
clinical manifestations of, 18-19
diagnosis of, 19-22
histopathology of, 8
lung biopsy and, 21-22
progressive systemic sclerosis and, 27-30
- Chronic obstructive pulmonary disease**, 1-7, 345-46
lung transplantation and, 1-7
- Churg-Strauss syndrome**, 421
- Clustering**
of suicides, 39
- Coagulation**, 325-35
factor VIII and, 325-35
thrombin and, 325-35
von Willebrand's factor and, 325, 329-30
- Colitis**
ulcerative, 125-31
See also Inflammatory bowel disease
- Collagen**, 269-77
formation of, 272-73
type I, 269-77
osteogenesis imperfecta and, 269-77
- Collagen genes**
mutations of, 269-77
osteogenesis imperfecta and, 269-77
- Collagen vascular disease**
chronic interstitial lung disease and, 17-32
therapy for, 31-32
- Colon cancer**, 61-68
diet and, 61-62
dominant oncogenes and, 61-63
ras gene and, 63

Computed tomographic scanning, 17-29, 195-96, 200-2
high-resolution thin-section, 17, 20, 22-23, 29
Computed tomography, 17-29, 195-96, 200-2
phantom, 195
Conjunctivitis
Lyme disease and, 98
Continuous positive airway pressure, 356-57, 360
Controlled mandatory ventilation, 353-55
Crohn's disease, 125-31
See also Inflammatory bowel disease
Cryoprotection
kidney preservation for
transplantation and, 523, 532-34
Cushing's disease
suicide and, 42
Cyclosporine A
treatment of inflammatory bowel disease with, 129
Cystic fibrosis
heart-lung transplantation and, 1-3
Cytochalasin B, 379
Cytochrome b, 117, 119-22
Cytokine antagonists
treatment of inflammatory bowel disease with, 131
Cytomegalovirus
susceptibility to
transplant patients and, 426-27

D

Demyelinating neuropathies
Lyme disease and, 97-98
Dendritic cells, 105-7
Langerhans' cells and, 106-7
pulmonary, 105-7
Dentinogenesis imperfecta
osteogenesis imperfecta and, 270, 272
Dermatomyositis, 25-27, 30
chronic interstitial lung disease and, 26-27, 30
Dermatan sulfate, 13
Devascularization and transection operation
esophageal variceal bleed and, 69, 73-75, 77-79
Diabetes mellitus, 377, 388-90, 395-413
heritable disorders in glucose transport and, 388-90
pancreas transplantation therapy for, 395-413

immunosuppressive drugs
and, 412-13
impact on eyes of, 407
impact on kidneys of, 407-9
impact on nerves of, 407-10
Diagnosis
of Epstein-Barr virus infection, 437, 443-45
Diagnostics, 147-52
1,25-Dihydroxyvitamin D₃ 227-35
See also Calcitriol
Dominant oncogenes
colon cancer and, 61-63
DNA
microbial diagnosis with, 148-52
DNA gyrase inhibitors, 465
fluoroquinolones, 465-82
Duncan's syndrome, 441-42

E

Edmonston-Zagreb vaccine for measles, 461
Eisenmenger's syndrome
lung transplantation and, 1-3, 7
Electrocardiogram
high-resolution, 157-67
cardiac late potentials and, 157
signal-averaged, 157
Electrocardiographic late potentials
ventricular tachycardia and, 157-67
Electrophysiologic testing, 283-86, 295
cardiac disease and, 284
syncope evaluation and, 283-86
Emphysema
heart-lung transplantation and, 1
Encephalopathy
chronic
Lyme disease and, 97
Endarterectomy
carotid, 301, 311-12
Endothelial-dependent relaxing factor, 222
oxidized LDL and, 222
Enterobacteriaceae, 467, 469
Enzyme-linked immunosorbent method (ELISA), 95, 101
Lyme disease testing with, 95, 101
Eosinophilic granuloma, 105-6
Eosinophils, 209-17
allergic disease and, 209-17

immunity to schistosomiasis
and, 209-17
Epstein-Barr virus infections, 437-46
diagnosis of, 443-45
immunodeficiency and, 440-43
immunopathogenesis of, 439
infectious mononucleosis and complications of, 440-41
Erythema migrans, 93-95, 97
Borrelia burgdorferi and, 93-95, 97
Erythrocytes, 47-56
glycolytic enzymes and, 47-56
Erythrocytosis, 54-55
Erythropoiesis, 505-7
Erythropoietin, 512-14
Esophageal varices, 69-79
prognosis for patients with, 69-70
alcoholic cirrhosis and, 70
nonalcoholic cirrhosis and, 70
treatment of, 69-79
balloon tube tamponade, 69, 72, 79
devascularization and transection operation, 69, 73-75, 77-79
long-term, 75-77
pharmacological, 69-72, 77-79
portocaval shunts, 69-79
prophylactic, 77-79
sclerotherapy, 69-79
See also Liver disease
Estrogen, 239-48, 364
breast cancer and, 246-48
cardiovascular disease and, 239-42, 248
endometrial cancer and, 239, 245-46, 248
ovarian cancer and, 244-45, 248
with progestin, 240
replacement
risks and benefits of, 239-48
resistance to, 364
Exophthalmos
Grave's disease and, 487-94
Extracranial carotid stenosis, 301-13

F

Factor VIII, 325-35
hemophilia A and, 325-35
protein C and, 333

- regulation of
von Willebrand's factor
and, 329-30
synthesis of
hepatocyte and, 327
thrombin-activated, 331-33
von Willebrand's factor
and, 325, 329-30
Factor Xa, 11-13
Fainting, 283
Familial adenomatous polyposis,
63-68
colon cancer and, 63-68
Familial multiple endocrine neo-
plasia syndromes, 253-66
carcinoma and
medullary thyroid, 253,
263-65
parathyroid, 255-56
insulinoma and, 256
pheochromocytoma and, 263-
65
primary hyperparathyroidism
and, 253, 255-62
Zollinger-Ellison syndrome
and, 256
Fatty acid
antioxidants and, 219-24
Fcε receptors
allergic disease and, 209-17
Fibrin, 9, 11, 14
Fibrinogen, 9
Fibrosis, 417
Filariasis, 417, 421
Foam cell formation, 220-21
Fluoroquinolone antibacterial
agents, 465-82
bone and joint infections and,
475
gastrointestinal infections and,
474-75
respiratory tract infections
and, 479-80
sexually transmitted diseases
and, 474
skin and soft tissue infections
and, 475
urinary tract infections and,
473-74
Framingham Study
syncope data from, 284
G
Galactosemia, 56
Gallium-67 scanning
alveolitis and, 17, 21, 29
Gardner's syndrome, 63-64
Gastritis
Helicobacter pylori infection
and, 135-43
Gene probes, 147-52
Generalized resistance to thyroid
hormone, 363-72
diagnosis of, 365, 367-68
mutation and, 363, 368-72
treatment of, 372
Globin genes
human, 497-504
beta-globin locus control
region and, 502-4
local *cis*-active control ele-
ments and, 502
Glomerular injury
cholesterol-induced, 83-91
pathology of, 86-87
Glomerulosclerosis, 83-91
hypercholesterolemia and, 83-
91
Glucocorticoids
resistance to, 364
D-Glucose, 377-90
Glucose-galactose malabsorption
familial, 377, 386-88
molecular basis for, 388
Glucose-6-phosphate de-
hydrogenase (G6PD), 47-
56, 256-57, 261-63, 265
deficiency of, 47-56
gene for, 48
mutations in, 49-56
hemolytic anemia and, 53-
56
tumor clonality and, 256-57,
261-62, 265
Glucose transporters, 277-90
human disorders and, 385-
90
Glutathione-S-transferase
immunity to schistosomes
and, 209-17
Glycemia
abnormal
pancreas transplantation
and, 396-413
GP1Ib/IIIa
monoclonal antibody to,
175
platelet aggregation and, 171-
75
Granuloma, 195-96
Granulomatosis
pulmonary Langerhans' cell,
105-13
Granulomatous disease
chronic, 117-22
cytochrome *b* and, 117,
119-22
interferon-gamma and, 117,
121-22
NADPH-oxidase and, 117-
22
Grave's eye disease, 487
Guillain-Barré syndrome, 440-
41
H
Hand-Schüller-Christian syn-
drome, 105
Hearing loss
osteogenesis imperfecta and,
270, 272
Heart-lung transplantation, 1-7,
431-32
Lung Transplant Registry in-
dicators for, 2
pulmonary complications of,
431-32
recipient selection guidelines
for, 4-5
survival statistics for, 1, 6-7
timing of, 5-6
Helicobacter pylori infection
diagnosis and therapy, 142-43
epidemiology, 138
gastroduodenal disease and,
135-43
pathogenesis of, 139-42
Hemoglobin
control of production of, 504-
7
inherited disorders affecting,
497-515
synthesis of, 500-4
Hemoglobin gene switching,
507-15
Hemoglobinopathies, 497-515
Hemolytic anemia
chronic
red cell enzyme deficien-
cies and, 53-56
Hemophilia A, 325-35
factor VIII deficiency and,
325-35
Hemostasis
factor VIII and, 325-35
thrombin and, 9
Heparin, 9-13, 175-77
half-life of, 10-11
low-molecular-weight, 11
mechanism of action of, 9-10
pharmacokinetics of, 10-11
Heparin-antithrombin III com-
plex, 9-11
Heparinoids, 11-13
dermaton sulfate, 13
ORG 10172, 13
Hereditary polyposis syndrome,
61-68
Herpesviruses
Epstein-Barr virus, 437-46
High-frequency ventilation, 359-
60
High-resolution thin-section
computed tomographic
scanning, 17, 20, 22-23,
29
Hirudin, 11, 13-14, 175, 178-79

- Hispanics
suicide and homicide rates
among, 38
- Histiocytosis X
See Langerhans' cell granulomatosis
- Hormone resistance, 363-72
c-erb-A proto-oncogene and, 364
- Hybridization protection assay, 149-51
- Hydroxychloroquine, 129
treatment of inflammatory bowel disease with, 129
- Hydroxyurea, 509-11, 513-14
- Hyperactivity, 363, 365
generalized resistance to thyroid hormone and, 365
- Hypercholesterolemia
oxidized low-density lipoproteins and, 219-24
progressive glomerular injury and, 83-91
- Hyperparathyroidism, 253, 255-62, 227-35
primary, 255-56
secondary
renal calcitriol synthesis and, 227-35
- Hypertension
pulmonary
lung transplantation and, 1-7
- Hyperthyroidism
Grave's disease and, 487-88
- I**
- Idiopathic hypereosinophilic syndrome, 423
- Idiopathic pulmonary fibrosis, 18
- IgA antibody, 209-17
immunity to schistosomes and, 209-17
- IgE antibody, 209-17
allergic disease and, 209-17
immunity to schistosomes and, 209-17
- IgG4 antibody
immunity to schistosomes and, 209-17
- Immunity
allergic disease, 209-17
schistosomiasis, 209-17
- Immunocompromised host organ transplantation and, 425, 437
Epstein-Barr infections and, 440-46
- Immunodeficiency
Epstein-Barr infections and, 440-46
- Infectious disease
treatment of
fluoroquinolone and, 465-82
- Inflammatory bowel disease, 125-31
drug therapy for
5-aminosalicylate (5-ASA), 126-31
immunosuppressive and immunomodulatory drugs for, 128-30
new preparations for, 126-27
new topical corticosteroids for, 127
sulfasalazine, 126-31
potential role of neuropeptides in inflammatory response and, 131
- Insulin resistance, 377, 388-90
- Insulin treatment
pancreas transplant vs, 395-413
- Insulinoma, 253, 256
- Interferon-gamma
recombinant human
chronic granulomatous disease and, 117, 121-22
- Interstitial pneumonitis, 17-32
cellular, 18
chest radiographs and, 17, 19
pulmonary function tests and, 17, 19
rheumatoid arthritis and, 23-26
- Inverse ratio ventilation, 357-59
- Ischemia
acute renal failure and, 523-42
- Ischemic attack
transient
anticoagulant therapy for, 310
antiplatelet therapy for, 311
endarterectomy for, 311-12
evaluation of patients with, 302-5
prognosis of patients with, 308-10
- Ixodes*
Borrelia burgdorferi and, 94
Lyme disease and, 94
- K**
- Kidney transplantation
pulmonary complications of, 430-31
See also Renal
- L**
- Langerhans' cell granulomatosis, 105-6
pathogenesis of, 110-12
pathology of, 107-9
pulmonary, 105-13
smoking and, 109
- Langerhans' cell histiocytosis
See Langerhans' cell granulomatosis
- Langerhans' cells
dendritic cells and, 106-7
- Lecithin-cholesterol-acyltransferase (LCAT) deficiency, 84
- Letterer-Siwe disease, 105
- Leukotriene B₄
inflammatory bowel disease and, 130
- Li-Fraumeni syndrome, 184
- Ligase chain reaction, 151
- Lipid peroxidation, 219-23
- Lipids, 83-91
glomerulosclerosis and, 83-91
- Lipoprotein
oxidized low-density
glomerulosclerosis and, 83-91
- Lipoxygenase, 219
- Liver disease
cirrhotic, 69-80
alcoholic, 70
Child's risk grading of, 70, 78
nonalcoholic, 70
See also Esophageal varices
- Liver transplantation, 75-76, 79, 430
pulmonary complications of, 430
- Löffler's syndrome, 421-22
- Low-density lipoprotein
oxidized, 83-91, 221-24
endothelium-dependent
relaxing factor and, 222
glomerulosclerosis and, 83-91
injury to mesangium and, 87-91
pathogenesis of atherosclerosis and, 219-24
- Low-molecular-weight heparins, 11-13
- Lung diseases
Langerhans' cell granulomatosis, 105-13
- Lung injury
acute, 353
- Lung Transplant Registry, 2
- Lung transplantation, 1-7, 431-32

- double, 1-7
heart-, 1-7
Lung Transplant Registry indications for, 2
pulmonary complications of, 431-42
recipient selection guidelines for, 4-5
single, 1-7
timing of, 5-6
Lyme disease, 93-102
arthritis and, 93, 98-99
Borrelia lymphocytoma and, 96
cardiac involvement in, 99-100
chronic neuroborreliosis and, 97
cutaneous manifestations of, 95-96
diagnosis and treatment of, 101-2
erythema migrans and, 93-95, 97
eye involvement in, 98
hepatic involvement in, 100
infectious arthritis and, 93, 98-99
lymphoid organs and, 100
neurological syndromes and, 96-98
Lymphoproliferative disorders, 437, 443-46
Epstein-Barr virus infection and, 437, 443
- M**
- Macrophages, 83-84, 86-91, 117, 209-17
accumulation of cholesterol by, 217-21
foam cell formation and, 220-21
oxidized low-density lipoproteins and, 221-24
glomerular, 83-84, 86-91
hypercholesterolemia and, 83-84, 86-91
schistosomiasis immunity and, 209-17
Measles, 451-62
deaths associated with, 455-56
epidemiology of, 452-57
resurgence of, 457
vaccine for, 454-62
AIK-C, 461
Edmonston-Zagreb, 461
new, 460-62
Schwarz, 461
- Medullary thyroid carcinoma, 253, 263-65
- Mesangium
oxidized low-density lipoprotein and injury to, 87-91
Microatelectasis, 342-43
Microbial nucleic acids
diagnosis via, 147-52
Mixed connective tissue disease, 27
- Meningitis
chronic
Lyme disease and, 97
- Mononucleosis
infectious, 437, 439-41
acute, 440
acute fatal, 441
complications of, 440-41
heterophile-positive, 439-40
- Montauk knee, 94
- Multiple endocrine neoplasia syndromes
familial, 253-66
- Mutation, 49-56, 269-77, 363, 368-72
glucose-6-phosphate dehydrogenase, 49-56
red cell enzyme defects and, 49-56
in hormone-binding domain of thyroid hormone receptors, 363, 368-72
type I collagen gene osteogenesis imperfecta and, 269-77
- Myocardial infarction
cardiac late potentials and, 157
- Mycoplasma pneumoniae*, 317-18
- N**
- NADP diaphorase deficiency, 56
NADPH-oxidase, 117-22
- Neoplasia
multiple endocrine, 253-66
familial, 253-66
- Nephrosis, 83-91
hypercholesterolemia and, 83-91
- Nephrotic syndrome, 83-91
Neuroborreliosis
chronic, 96-98
- Neuropathy
demyelinating, 97-98
Lyme disease and, 94, 96-98
- Neutrophil, 117
- Noninvasive ventilation, 360
- Nucleic acid amplification, 147-52
- O**
- Olsalazine
treatment of inflammatory bowel disease with, 126
- Oncogenes
dominant
colon carcinogenesis and, 61-63
- Ophthalmopathy, 487-94
Grave's disease and, 487-94
thyroid-associated, 487-94
- ORG 10172, 13
- Organ preservation, 523-42
kidney, 523-42
nonperfusion storage and, 532-34
perfusion storage and, 532-34
preservation solutions for compositions of, 534-42
- Osteitis, 219, 231, 32
parathyroid hormone and, 231-32
- Osteogenesis imperfecta, 269-81
chorionic villus sampling and, 271
molecular basis of, 272-73
phenotypic presentation of, 269-72, 276-77
treatment of, 277-80
- Osteopenia, 269-81
- Osteoporosis, 239, 242-44
estrogen replacement and, 239, 242-44, 248
- Oxygenation failure, 344-45
- P**
- Pancreas allografts
human, 395-413
immunosuppressive drug use with, 412-13
- Pancreas Transplant Registry, 397
- Parathyroid hormone, 227-35
osteitis and, 231-32
- Parathyroid hormone gene, 261
- Peptic ulcer
Helicobacter pylori infection and, 135-43
- Periarteritis nodosa, 421
- Phagocytes, 117-22
interferon-gamma and, 121-22
- Phenothiazines, 542
- Pheochromocytoma, 253, 263-65
- Phlorizin, 379
- Pituitary
resistance to thyroid hormone and, 365
- Platelet factor, 4, 10
- Platelets, 171-79, 209-17
allergic disease and, 209-10

- IgE antibody and schistosome larvae and, 209-17
 physiology of, 172-74
 thrombosis and, 171-79
Pneumocystis carinii
 complications of transplantation and, 426-27
 Pneumonia, 18, 317-23, 423, 425-27
 atypical, 317
 bronchiolitis obliterans organizing, 18
 chronic eosinophilic, 423
 incidence of, 317-18
 transplantation and, 425-27
 from TWAR species of *Chlamydia pneumoniae*, 317-23
 Polymrase chain reaction, 148-51
 Polymyositis
 chronic interstitial lung disease and, 26-27, 30
 Polyposis
 familial adenomatous, 63-68
 Polyposis syndromes
 hereditary, 61-68
 Portocaval shunts, 69-79
 esophageal variceal bleed and, 69
 Positive end-expiratory pressure, 345, 349-51, 356-58
 auto-, 347-51, 353-54, 357
 Positive pressure ventilation, 342-60
 PPACK, 14
 Preschool children
 measles among, 451-62
 resurgence of, 457-58
 vaccine for, 454-62
 Pressure-supported ventilation, 355-56
 Progesterone
 resistance to, 364
 Programmed electrical stimulation, 164
 Progressive systemic sclerosis, 27-30
 chronic interstitial lung disease and, 27-30
 Proptosis
 Grave's disease and, 487-94
 Protein C deficiency, 333
 thrombotic disease and, 333
 Proteinuria, 83-86
 Pseudohypoparathyroidism, 363
 Pulmonary complications of organ transplantation, 425-33
 Pulmonary diseases
 end-stage
 heart-lung transplantation and, 1-7
 Pulmonary fibrosis
 collagen vascular disease and, 17
 Pulmonary function tests, 17, 19
 Pulmonary infiltrates with eosinophilia (PIE), 417-23
 Pulmonary Langerhans' cell granulomatosis, 105-13
 See also Langerhans' cell granulomatosis
 Pulmonary vascular diseases
 heart-lung transplantation and, 1-7
 Pyruvate kinase deficiency, 56
 R
ras genes
 colon cancer and, 63-66
 Ha-, 63
 Ki-, 63
 N-, 63
 Reactive oxygen species, 529-32
 Red cells
 enzyme defects of, 47-56
 galactosemia, 56
 glucose-6-phosphate dehydrogenase deficiency, 47-56
 NADP diaphorase deficiency, 56
 pyruvate kinase deficiency, 56
 Reflux
 aortic, 303
 mitral, 303
 Renal disease
 calcitriol and, 227-35
 vitamin D and, 228-35
 Renal failure
 ischemic acute, 523-42
 Renal glycosuria, 377, 385-88
 glucose transport and heritable abnormalities in, 385
 Renal osteodystrophy, 227, 231-32
 Resistance
 to antibiotics, 465, 467-69
 Respirator, 341-60
 Respiratory burst, 117
 Respiratory distress syndrome
 adult, 341, 344-45, 347, 352
 Respiratory failure, 341-60
 Respiratory infection
 lower
 Chlamydiae and, 317-23
 Restriction length polymorphism analysis
 familial multiple endocrine neoplasia syndromes and, 254, 257-62
 Retinoblastoma, 254-56
 familial, 254
 sporadic, 254
 Reye's syndrome, 441
 Rheumatoid arthritis
 chronic interstitial lung disease and, 23-26
 RNA
 microbial diagnosis with, 148-52
 S
 Scavenger receptor, 219-21
 Schistosomes
 immunity to, 209-17
 antibody-dependent, cell-mediated cytotoxicity and, 211-13
 Schistosomiasis, 70, 209-17
 esophageal variceal bleeding and, 70
 immunologic aspects of, 209-17
 Schwarz vaccine for measles, 461
 Sclerae
 blue
 osteogenesis imperfecta and, 270-71
 Sclerotherapy, 69-79
 esophageal variceal bleed and, 60
 Secondary hyperparathyroidism, 227-35
 renal calcitriol synthesis and, 227-35
 Sickle cell anemia
 fetal hemoglobin and, 498-500
 Sinusitis
 Chlamydia pneumoniae and, 317-23
 Sjögren's syndrome, 30
 Smoking
 risk for solitary pulmonary nodule from, 197-98
 Solitary pulmonary nodule, 195-206
 doubling time of, 199-200
 etiology of, 196-97
 incidence of, 196
 prognosis of, 198
 risk factors, 197-98
 smoking, 197-98
 Sputum cytology, 202-3
 Stenosis
 aortic, 303

- extracranial carotid, 301-13
 mitral, 303
 Stroke, 301-13
 Substance abuse
 suicide and, 38, 40
 Suicide, 37-43
 adolescents and, 38-40
 alcohol dependence and, 40
 child abuse and, 38
 clustering, 39
 economics and, 39
 epidemiology of, 37-40
 homicide and, 38
 international perspective on, 39
 marital status and, 39
 medical patients and, 41-42
 Northern Europeans and, 39
 prevention of, 42-43
 psychiatric populations and, 40-41
 US rates of, 37-38
 age differences in, 38
 European descent and, 39
 race and, 38-39
 religion and, 39
 sex differences in, 38-40
 Sulfasalazine
 treatment of inflammatory bowel disease with, 126-27
 Superoxide, 117
 Synchronized intermittent mandatory ventilation, 344, 351, 35
 Syncope, 165, 283-97
 cardiac late potentials and, 167
 electrophysiologic testing for, 283-86, 294
 incidence of, 284-92
 cardiac hemodynamic/
 valvular disturbances
 and, 287, 289
 cardiac rhythm disturbances
 and, 286-88
 cerebrovascular disturbances
 and, 287, 290
 noncardiovascular disorders
 and, 287, 291-92
 vascular disturbances and,
 287, 289
 neurally mediated reflex, 286-87, 290-91, 295
 treatment of, 296-97
 Systemic lupus erythematosus, 31
 T
 Tachycardia
 ventricular, 157
 cardiac late potentials and, 157
 Tamoxifen
 breast cancer and
 prevention of, 188-92
 Thoracotomy, 204-5
 Thrombin, 9-14, 325-35
 activation of factor VIII and,
 325-35
 activation of protein C by,
 333
 Thrombin inhibitors, 9-14
 argatroban, 14
 dermatan sulfate, 13
 heparin, 9-13, 175-77
 low-molecular-weight, 11-13
 heparinoids, 11-13
 hirudin, 11, 13-14, 175, 178-79
 novel, 11-14
 ORG 10172, 13
 PPACK, 14
 Thrombogenesis, 9
 Thrombosis, 171-79
 Thrombotic disorders
 anticoagulants and, 9-14
 Thyroid hormone
 mechanism of action of, 368
 v-erb-A and, 368
 Thyroid hormone auxiliary protein, 369-71
 Thyroid hormone receptor, 368-71
 Thyroid hormone resistance, 363-72
 c-erb-A proto-oncogene and, 364
 peripheral tissues and, 365
 Thyrotropin, 363, 365-69, 372
 Thyrotropin-releasing hormone, 365, 367-68
 Thyroxine-binding globulin, 367
 Ticlopidine, 171, 175-78
 Tilt-table testing, 283
 Tomography 17, 20, 22-23, 29, 195-96, 200-2
 high-resolution thin-section
 computed, 17, 20, 22-23, 29
 solitary pulmonary nodules
 and, 195-96, 200-2
 Transient ischemic attack, 301-13
 anticoagulant therapy for, 310
 antiplatelet therapy for, 311
 endarterectomy for, 311-12
 evaluation of patients with,
 302-5
 ultrasound and, 302-5
 prognosis of patients with,
 308-10
 Transplant complications
 bone marrow
 Epstein-Barr virus and, 438
 pulmonary, 425-33
 Transplantation, 1-7, 425-33, 523-42
 bone marrow, 428-30, 438
 heart-lung, 1-7, 431-32
 kidney, 430-31, 523-42
 preservation *ex vivo* for,
 523-42
 lung, 1-7, 431-32
 pulmonary complications of,
 425-33
 See also Allografts
 Transthoracic needle aspiration biopsy, 204
 Tropical pulmonary eosinophilia syndrome, 417-23
 differential diagnosis of, 420-21
 treatment of, 421-23
 Tumor suppressor genes, 61, 63-68
 chromosomal allelic losses
 and, 63-68
 colon carcinogenesis and, 61-68
 TWAR species of *Chlamydia pneumoniae*, 317-23
 laboratory diagnosis of, 321-23
 treatment of, 322
 U
 Ulcer
 peptic, 135-43
 Helicobacter pylori infection and, 135-43
 Ulcerative colitis, 125-31
 See also Inflammatory bowel disease
 Ultrasound
 B-mode, 301-2, 304-5
 Doppler, 301-5, 312-13
 United Network for Organ Sharing, 399
 V
 Vaccine, 214-17, 254-62
 measles, 454-62
 increasing coverage of, 458
 new, 460-62
 recommendations for, 458-62
 status of, 454-56
 schistosomiasis immunity,
 209-10, 214-17
 AIDS and, 217
 Valsalva maneuver
 syncope evaluation and, 296
 Ventilation
 assisted/controlled, 353
 assisted mandatory, 343-44

controlled mandatory, 353
 high-frequency, 359-60
 inverse ratio, 357-59
 mechanical
 clinical uses of, 343-46
 complications of, 347-53
 noninvasive, 360
 positive end-expiratory pressure and, 345, 349-51, 356-58
 positive pressure, 342-60
 pressure-supported, 355-56
 synchronized intermittent mandatory, 344, 351, 355

Ventilatory support, 341-60
 positive pressure, 342-60
 Ventricular tachycardia, 157
 cardiac late potentials and, 157
 v-erb-A
 mechanism of thyroid hormone action and, 368
 Vitamin D
 renal disease and, 228-35
 resistance to, 364
 von Willebrand's factor, 325, 329-30
 regulation of factor VIII by, 329-30

W

Wagner's granulomatosis, 421
Wucheria bancrofti, 417-19, 421

X

X-linked lymphoproliferative syndrome, 441-43

Z

Zollinger-Ellison syndrome, 253, 256